Breaking Finance News

ValuEngine upgraded The Medicines Company (NASDAQ:MDCO) to Sell in a report released today.

ValuEngine has upgraded The Medicines Company (NASDAQ:MDCO) to Sell in a report released on Friday June 02, 2017.

Previously on Tuesday May 23, 2017, CIBC released a statement about The Medicines Company (NASDAQ:MDCO) increased the target price from $0.00 to $50.00. At the time, this indicated a possible upside of 0.22%.

Just yesterday The Medicines Company (NASDAQ:MDCO) traded -1.36% lower at $40.19. The Medicines Company’s 50-day moving average is $35.89 and its 200-day moving average is $40.15. The last stock price is up -15.37% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 954,322 shares of MDCO traded hands, down from an average trading volume of 1,225,420

Recent Performance Chart

The Medicines Company (NASDAQ:MDCO)

The Medicines Company has 52 week low of $30.80 and a 52 week high of $55.95 and has a market capitalization of $0.

In addition to ValuEngine reporting its stock price target, a total of 9 brokerages have issued a ratings update on the company. The average stock price target is $47.56 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On The Medicines Company (NASDAQ:MDCO)

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.